Moderator of the session, Sam S. Chang, MD, MBA, Professor of Urologic Surgery at Vanderbilt University Medical Center, Nashville, and American Urological Association spokesperson, said that due to these results he would definitely consider this treatment option for both high-risk and African American patients. “Radiation is a localized treatment,” explained Dr. Chang, “and these high-risk patients don’t fail locally; they fail systemically. I will unquestionably tell my patients we should at least consider adjuvant chemotherapy.”
Dr. Chang concluded: “With this population, there’s a good chance that oncologists will need to use all the weapons at their disposal, and if adjuvant therapy delays the time of failure by 18 months or 2 years, then it’s definitely something we should discuss.” ■
Disclosure: Dr. Chang is on the advisory board of Astellas and Janssen.
A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...